Shares of AMAG Pharmaceuticals, Inc. (AMAG) traded as low as $37.70 today, down nearly 17% from the prior close of $45.25 due to purported safety concerns regarding Feraheme® , the company’s marketed product for the treatment of iron deficiency anemia in adult patients with chronic kidney disease . Despite the use of recombinant...
Read More »